ETNB News and Press, 89bio Inc. From 04/29/23

2023-04-29 08:25:00 ET 89bio (NASDAQ: ETNB) , Karuna Therapeutics (NASDAQ: KRTX) , and Morphic Therapeutics (NASDAQ: MORF) are clinical-stage biotech companies that make attractive buyout targets. Their financial positions may not be great, as they all have littl...

2023-04-23 12:00:00 ET Biotech deal-making is on a roll, with more than $12B worth of transactions announced over the past week alone, and, according to industry observers, the trend is expected to continue in 2023, supported by macro and certain industry-specific factors. Days after Me...

89bio, Inc. (NASDAQ: ETNB) is the focus of IBN's latest stock spotlight. The company's shares have moved 0% on the day to $17.07. 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabol...

89bio, Inc. (NASDAQ: ETNB) is the focus of IBN's latest stock spotlight. The company's shares have moved -3.28% on the day to $14.46. 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-met...

2023-03-29 23:40:24 ET Summary NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient population is forecast to increase from 16 million i...

2023-03-24 10:57:41 ET Shares of clinical-stage biopharmaceutical company 89bio (NASDAQ: ETNB) were up 36.2% for the week as of Friday morning, according to data provided by S&P Global Market Intelligence . The stock is up more than 326% over the past 12 months. It closed la...

2023-03-24 08:12:28 ET 89bio ( NASDAQ: ETNB ) has priced an underwritten public offering of 16,923,077 shares of its common stock at $16.25/share. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 2,538,461 shares. Gross pr...

SAN FRANCISCO, March 24, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the p...

2023-03-23 13:25:58 ET For a second day, 89bio ( NASDAQ: ETNB ) is seeing major gains -- up 22% in Thursday afternoon trading -- following mid-stage data on nonalcoholic steatohepatitis ( NASH ) candidate pegozafermin and several Street firms boosted their pr...

2023-03-23 12:47:58 ET Gainers: DiamondHead Holdings ( DHHCU ) +111% . DiamondHead Holdings ( DHHC ) +91% . Boxed BOXD +88% . ZyVersa Therapeutics ZVSA +33% . Amprius Technologies ( AMPX ) +30% . Kineta ( KA ) +29% . ...